摘要
目的:观察血必净联合乌斯他丁对全身炎症反应综合征的临床疗效。方法:68例全身炎症反应综合征(SIRS)患者随机分为血必净联合乌斯他丁治疗组(实验组)和乌斯他丁治疗组(对照组),治疗前和治疗后第2、4、6天观察APACHEⅡ评分、血清C反应蛋白(CRP)、凝血功能(APTT、PT、PLT等)等指标。结果:在治疗后第4、8天,实验组与对照组相比较,治疗组APACHEⅡ评分、CRP明显下降,凝血功能明显改善,具有统计学意义(P<0.05)。结论:血必净联合乌斯他丁能有效阻断SIRS病理过程,改善SIRS患者病情。
Objective： To evaluate the clinical therapeutic effect of combination Xuebijing and ulinastatin in patients with systemic inflammatory respose syndrome .Methods：68 patients with SIRS were randomly divided into Xuebijing combinated ulinastatin treatment group （experimental group） and ulinastatin treatment group （control group）,in the different time, the APACHE Ⅱ ,the CRP of plasma and the cruor function （APTT,PLT,PT） were determined.Results： eomparised experimental group with control group ,APACHE Ⅱ and CRP were decreased and the eruor function was improved,there were significant diferences （P 〈0.05）.Conelusion：Xuebijing combinated ulinastatin can interdict the patho-course of SIRS, improve curative effect of the patients with SIRS .
出处
《实用中西医结合临床》
2010年第1期3-4,共2页
Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
